Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Conditions:   Refractory or Recurrent Solid Tumors;   Rhabdomyosarcoma;   Non-Rhabdomyosarcoma Soft Tissue Sarcoma Interventions:   Drug: Eribulin mesilate;   Drug: Irinotecan hydrochloride Sponsor:   Eisai Inc. Recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials